1. Home
  2. ZBAI vs INDP Comparison

ZBAI vs INDP Comparison

Compare ZBAI & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZBAI
  • INDP
  • Stock Information
  • Founded
  • ZBAI 2015
  • INDP 2000
  • Country
  • ZBAI United States
  • INDP United States
  • Employees
  • ZBAI N/A
  • INDP N/A
  • Industry
  • ZBAI Professional Services
  • INDP Biotechnology: Pharmaceutical Preparations
  • Sector
  • ZBAI Consumer Discretionary
  • INDP Health Care
  • Exchange
  • ZBAI Nasdaq
  • INDP Nasdaq
  • Market Cap
  • ZBAI 6.4M
  • INDP 6.0M
  • IPO Year
  • ZBAI N/A
  • INDP N/A
  • Fundamental
  • Price
  • ZBAI $0.38
  • INDP $10.34
  • Analyst Decision
  • ZBAI
  • INDP Strong Buy
  • Analyst Count
  • ZBAI 0
  • INDP 2
  • Target Price
  • ZBAI N/A
  • INDP $238.00
  • AVG Volume (30 Days)
  • ZBAI 8.3M
  • INDP 24.8K
  • Earning Date
  • ZBAI 06-06-2025
  • INDP 08-11-2025
  • Dividend Yield
  • ZBAI N/A
  • INDP N/A
  • EPS Growth
  • ZBAI N/A
  • INDP N/A
  • EPS
  • ZBAI N/A
  • INDP N/A
  • Revenue
  • ZBAI $720,000.00
  • INDP N/A
  • Revenue This Year
  • ZBAI N/A
  • INDP N/A
  • Revenue Next Year
  • ZBAI N/A
  • INDP N/A
  • P/E Ratio
  • ZBAI N/A
  • INDP N/A
  • Revenue Growth
  • ZBAI 44.00
  • INDP N/A
  • 52 Week Low
  • ZBAI $0.27
  • INDP $7.56
  • 52 Week High
  • ZBAI $2.50
  • INDP $59.36
  • Technical
  • Relative Strength Index (RSI)
  • ZBAI N/A
  • INDP 45.64
  • Support Level
  • ZBAI N/A
  • INDP $9.62
  • Resistance Level
  • ZBAI N/A
  • INDP $10.91
  • Average True Range (ATR)
  • ZBAI 0.00
  • INDP 0.82
  • MACD
  • ZBAI 0.00
  • INDP -0.23
  • Stochastic Oscillator
  • ZBAI 0.00
  • INDP 19.05

About ZBAI ATIF Holdings Limited Ordinary Shares

ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Share on Social Networks: